69 related articles for article (PubMed ID: 35342129)
1. Tyrosine kinase inhibitor-induced hypertension-marker of anti-tumour treatment efficacy or cardiovascular risk factor?
Ptinopoulou AG; Sprangers B
Clin Kidney J; 2021 Jan; 14(1):14-17. PubMed ID: 33564402
[TBL] [Abstract][Full Text] [Related]
2. Anti-VEGF Cancer Therapy in Nephrology Practice.
Izzedine H
Int J Nephrol; 2014; 2014():143426. PubMed ID: 25210627
[TBL] [Abstract][Full Text] [Related]
3. Thrombotic microangiopathy associated with lenvatinib therapy.
Contreras Angulo M; García Izquierdo B; Armengod Grao L; Palacios García N
Endocr Oncol; 2023 Jan; 3(1):e220078. PubMed ID: 37434645
[TBL] [Abstract][Full Text] [Related]
4. Thrombotic Microangiopathy, Podocytopathy, and Damage to the Renal Tubules with Severe Proteinuria and Acute Renal Dysfunction Induced by Lenvatinib.
Nakashima S; Sekine A; Sawa N; Kawamura Y; Kono K; Kinowaki K; Kawada M; Hasegawa E; Akuta N; Suzuki Y; Ohashi K; Takaichi K; Ubara Y; Hoshino J
Intern Med; 2022 Oct; 61(20):3083-3088. PubMed ID: 35342129
[TBL] [Abstract][Full Text] [Related]
5. Thrombotic Microangiopathy with Severe Proteinuria Induced by Lenvatinib for Radioactive Iodine-Refractory Papillary Thyroid Carcinoma.
Hyogo Y; Kiyota N; Otsuki N; Goto S; Imamura Y; Chayahara N; Toyoda M; Nibu KI; Hyodo T; Hara S; Masuoka H; Kasahara T; Ito Y; Miya A; Hirokawa M; Miyauchi A; Minami H
Case Rep Oncol; 2018; 11(3):735-741. PubMed ID: 30519176
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and management of proteinuria associated with vascular endothelial growth factor receptor-targeted tyrosine kinase inhibitor treatment in advanced renal cell carcinoma, hepatocellular carcinoma, and thyroid cancer.
Kato T; Mizuno R; Miyake H
Int J Urol; 2024 May; 31(5):465-474. PubMed ID: 38318663
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
[TBL] [Abstract][Full Text] [Related]
9. Lenvatinib-related renal microangiopathy: a case series.
Delsante M; Monroy-Trujillo JM; Carter-Monroe N; Ball DW; Rosenberg AZ
Virchows Arch; 2022 Feb; 480(2):467-473. PubMed ID: 33959820
[TBL] [Abstract][Full Text] [Related]
10. Characteristic Renal Histology of a 81-Year-Old Patient with a 30-Year History of Diabetes Mellitus: A Case Report.
Shima N; Sawa N; Yamanouchi M; Mizuno H; Kawada M; Sekine A; Hiramatsu R; Hayami N; Hasegawa E; Suwabe T; Hoshino J; Takaichi K; Ohashi K; Fujii T; Ubara Y
CEN Case Rep; 2020 Nov; 9(4):338-343. PubMed ID: 32361867
[TBL] [Abstract][Full Text] [Related]
11. Renal-Limited Thrombotic Microangiopathy due to Bevacizumab Therapy for Metastatic Colorectal Cancer: A Case Report.
Toriu N; Sekine A; Mizuno H; Hasegawa E; Yamanouchi M; Hiramatsu R; Hayami N; Hoshino J; Kawada M; Suwabe T; Sumida K; Sawa N; Takaichi K; Ohashi K; Fujii T; Matoba S; Ubara Y
Case Rep Oncol; 2019; 12(2):391-400. PubMed ID: 31244641
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
